Prevention of vascular cognitive impairment

Stroke

Volumn 43, Issue 11, 2012, Pages 3137-3146

  Dichgans, Martin ^a,b,c   Zietemann, Vera ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

cognitive impairment; dementia; prevention; vascular

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HOMOCYSTEINE; INDAPAMIDE; NIMODIPINE; PERINDOPRIL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; VITAMIN B GROUP;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; BODY MASS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; EDUCATIONAL STATUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; VASCULAR COGNITIVE IMPAIRMENT;

CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; HUMANS;

EID: 84868206426     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.651778     Document Type: Review

References (68)

1. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220-2241.
2. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-2713.
3. EClipSE Collaborative Members, Brayne C, Ince PG, Keage HA, McKeith IG, Matthews FE, et al. Education, the brain and dementia: neuroprotection or compensation? Brain. 2010;133:2210-2216.
4. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol. 2007;166:367-378.
5. Rusanen M, Kivipelto M, Quesenberry CP, Jr., Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med. 2011;171:333-339.
6. Nooyens AC, van Gelder BM, Verschuren WM. Smoking and cognitive decline among middle-aged men and women: the Doetinchem Cohort Study. Am J Public Health. 2008;98:2244-2250.
7. Gons RA, van Norden AG, de Laat KF, van Oudheusden LJ, van Uden IW, Zwiers MP, et al. Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. Brain. 2011;134:2116-2124.
8. Almeida OP, Garrido GJ, Alfonso H, Hulse G, Lautenschlager NT, Hankey GJ, et al. 24-month effect of smoking cessation on cognitive function and brain structure in later life. Neuroimage. 2011;55:1480-1489.
9. Morris MC. Nutritional determinants of cognitive aging and dementia. Proc Nutr Soc. 2011:1-13.
10. Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302:638-648.
11. Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC. Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr. 2011;93:601-607.
12. Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA. 2011;305:1348-1349.
13. Beard RS, Jr., Reynolds JJ, Bearden SE. Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptor-dependent regulation of adherens and tight junctions. Blood. 2011;118:2007-2014.
14. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Jacques PF, Selhub J, et al. Homocysteine and cognitive performance in the Framingham offspring study: age is important. Am J Epidemiol. 2005;162:644-653.
15. Ho RC, Cheung MW, Fu E, Win HH, Zaw MH, Ng A, et al. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry. 2011;19:607-617.
16. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464-472.
17. Aarsland D, Sardahaee FS, Anderssen S, Ballard C, Alzheimer's Society Systemic Review group. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health. 2010;14:386-395.
18. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008;300:1027-1037.
19. Williamson JD, Espeland M, Kritchevsky SB, Newman AB, King AC, Pahor M, et al. Changes in cognitive function in a randomized trial of physical activity: results of the lifestyle interventions and independence for elders pilot study. J Gerontol A Biol Sci Med Sci. 2009;64:688-694.
20. University of Florida. The LIFE Study: Lifestyle Interventions and Independence for Elders. In:ClinicalTrials.gov[Internet]. Bethesda, MD: National Library of Medicine (US);2011. NLM identifier:NCT01072500. Available at: http://clinicaltrials.gov/ct2/show/NCT01072500?term=NCT01072500&rank=1. Accessed January 16, 2011.
21. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011;12:e426-e437.
22. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057-1064.
23. Feldstein CA. Effects of blood pressure changes on Alzheimer's disease. Neuroepidemiology. 2010;35:202-212.
24. Stewart R, Xue QL, Masaki K, Petrovitch H, Ross GW, White LR, et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension. 2009;54:233-240.
25. Sharp SI, Aarsland D, Day S, Sonnesyn H, Alzheimer's Society Vascular Dementia Systematic Review Group, Ballard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry. 2011;26:661-669.
26. Guan JW, Huang CQ, Li YH, Wan CM, You C, Wang ZR, et al. No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies. J Alzheimers Dis. 2011;27:799-807.
27. Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension. 2010;55:1352-1359.
28. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37:1165-1170.
29. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology. 2009;72:1727-1734.
30. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging. 2001;22:407-412.
31. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915.
32. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56:991-996.
33. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63:686-692.
34. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.
35. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26:699-708.
36. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
37. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.
38. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.
39. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009:CD004034.
40. Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10:43-53.
41. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhager WH. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension. 2011;57:e6-e7.
42. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One. 2009;4:e4144.
43. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008;7:184-190.
44. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64-74.
45. Saczynski JS, Jonsdottir MK, Garcia ME, Jonsson PV, Peila R, Eiriksdottir G, et al. Cognitive impairment: an increasingly important complication of type 2 diabetes: the age, gene/environment susceptibility-Reykjavik study. Am J Epidemiol. 2008;168:1132-1139.
46. Cosentino F, Battista R, Scuteri A, De Sensi F, De Siati L, Di Russo C, et al. Impact of fasting glycemia and regional cerebral perfusion in diabetic subjects: a study with technetium-99m-ethyl cysteinate dimer single photon emission computed tomography. Stroke. 2009;40:306-308.
47. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009;66:300-305.
48. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10:969-977.
49. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
50. Evans GJ, Sastre AA. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2003:CD003804.
51. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr., Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565-1572.
52. Solomon A, Kareholt I, Ngandu T, Wolozin B, Macdonald SW, Winblad B, et al. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 2009;30:1006-1009.
53. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28:75-80.
54. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
55. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
56. Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, et al. Dementia after stroke: the Framingham Study. Stroke. 2004;35:1264-1268.
57. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006-1018.
58. Kuller LH, Lopez OL, Jagust WJ, Becker JT, DeKosky ST, Lyketsos C, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology. 2005;64:1548-1552.
59. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm. 2010;7:433-437.
60. Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, et al. Chronic kidney disease, cognitive decline, and incident dementia: The 3C Study. Neurology. 2011;77:2043-2051.
61. Guerchet M, Aboyans V, Nubukpo P, Lacroix P, Clement JP, Preux PM. Ankle-brachial index as a marker of cognitive impairment and dementia in general population. A systematic review. Atherosclerosis. 2011;216:251-257.
62. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875-884.
63. Richard E, Van den Heuvel E, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009;23:198-204.
64. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG.Cadasil. Lancet Neurol. 2009;8:643-653.
65. Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 2009;360:1729-1739.
66. Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310-318.
67. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 2009;40:S40-44.
68. A united approach to vascular disease and neurodegeneration. Lancet Neurol. 2012;11:293.